Brain

Physiotherapy Equipment Market is expected to generate a revenue of USD 14.88 Billion by 2031, Globally, at 6.6% CAGR: Verified Market Research®

Verified Market Research® proudly announces the release of its latest comprehensive market research report, "Physiotherapy Equipment Market," offering critical insights…

1 year ago

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024

BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology…

1 year ago

ONWARD® Medical Announces Third Implant of Brain-Computer Interface (BCI) System to Restore Movement after Spinal Cord Injury

Company continues pioneering research on BCI-enabled system to restore mobility after spinal cord injuryEINDHOVEN, The Netherlands, Sept. 19, 2024 (GLOBE…

1 year ago

Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage…

1 year ago

Neurohacker Announces Name Change To Qualia Life Sciences As Part Of Expansion

CARLSBAD, Calif., Sept. 18, 2024 /PRNewswire/ -- The pioneering health and wellness brand formerly known as Neurohacker Collective, has recently completed…

1 year ago

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company…

1 year ago

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting

Company to present new data, highlighting progress in its therapeutics program for recurrent glioblastoma (rGBM)AUSTIN, Texas, Sept. 18, 2024 (GLOBE…

1 year ago

Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia

The first-in-human Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic profile of ENX-104 in healthy volunteers…

1 year ago

Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

TORONTO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…

1 year ago

IRLAB Granted Additional Patent for its Drug Candidate Pirepemat Expanding the Patent Protection in the US

GOTHENBURG, SE / ACCESSWIRE / September 18, 2024 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, September 18, 2024 - IRLAB…

1 year ago